A feasibility study on the development of Psorax35 as the first and only oral treatment for mild-to-moderate psoriasis with positive effects on co-morbidities.

Project description

Development of the first oral treatment for mild-to-moderate psoriasis

Fields of science

• medical and health sciences › clinical medicine › rheumatology
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• medical and health sciences › health sciences › nutrition
• medical and health sciences › clinical medicine › cardiology › cardiovascular diseases

Programme(s)

• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme
• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

ARCTIC NUTRITION AS

Net EU contribution

€ 50 000,00

Address

Industrivegen 42
6155 Orsta
Norway

Region

Norge › Vestlandet › Møre og Romsdal

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Other funding

€ 21 429,00